Stopping chronic pain before it starts
This article was originally published in Start Up
Adynxx Inc.’s first clinical candidate is a one-time treatment to keep acute postoperative pain out of the brain. The same pain pathway-blocking strategy underlies a therapeutic pipeline the company plans to develop for the huge need for a better solution for the five million patients in the US who are treated for chronic pain annually.
You may also be interested in...
Clinical Data In 2014 Could Trigger Private Biotech Financings
Despite difficulties financing late-stage trials, several private companies are expecting Phase II and III data that should help shape public investor sentiment this year. Familiar compounds in new guises lead the way.
Deals Of The Week: Mylan/Agila, UCB/Biotie, Jazz/Concert…
Elan peels off assets to attract suitors: First Biogen buys out Elan’s 50% interest in Tysabri, then Royalty Pharma maneuvers to buy out Elan.
Pain Drug Development Becomes Personalized
Advances in pain neurobiology point to the promise of more specific drugs with fewer side effects, yet the field continues to show few successes. Nevertheless, fast-advancing knowledge, a huge market, and better clinical study de-risking strategies should eventually overcome investor shyness about backing emerging personalized pain drug developers.